Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Lexaria Bioscience, a Kelowna, Canada-based company that develops drug delivery platforms, is seeking a listing on the Nasdaq. The company is currently listed on the Over-the-Counter Markets under the ticker "LXRP," as well as the Canadian Securities Exchange under the ticker symbol "LXX."
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Large Accounts
| Latest market close | $6.45 |
|---|---|
| 52-week range | $4.11 - $10.50 |
| 50-day moving average | $6.55 |
| 200-day moving average | $6.24 |
| Wall St. target price | $12.75 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.97 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.45 from 2021-10-25
| 1 week (2021-10-19) | -5.29% |
|---|---|
| 1 month (2021-09-24) | -5.98% |
| 3 months (2021-07-26) | -4.73% |
| 6 months (2021-04-26) | 21.70% |
| 1 year (2020-10-26) | 3,386.49% |
|---|---|
| 2 years (2019-10-25) | 821.43% |
| 3 years (2018-10-26) | 330.00% |
| 5 years (2016-10-26) | 2,171.13% |
| Revenue TTM | $825,456 |
|---|---|
| Gross profit TTM | $276,925 |
| Return on assets TTM | -42.56% |
| Return on equity TTM | -54.36% |
| Profit margin | 0% |
| Book value | $2.03 |
| Market capitalisation | $37.7 million |
TTM: trailing 12 months
There are currently 338,984 Lexaria Bioscience shares held short by investors – that's known as Lexaria Bioscience's "short interest". This figure is 5.5% down from 358,862 last month.
There are a few different ways that this level of interest in shorting Lexaria Bioscience shares can be evaluated.
Lexaria Bioscience's "short interest ratio" (SIR) is the quantity of Lexaria Bioscience shares currently shorted divided by the average quantity of Lexaria Bioscience shares traded daily (recently around 325946.15384615). Lexaria Bioscience's SIR currently stands at 1.04. In other words for every 100,000 Lexaria Bioscience shares traded daily on the market, roughly 1040 shares are currently held short.
To gain some more context, you can compare Lexaria Bioscience's short interest ratio against those of similar companies.
However Lexaria Bioscience's short interest can also be evaluated against the total number of Lexaria Bioscience shares, or, against the total number of tradable Lexaria Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lexaria Bioscience's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Lexaria Bioscience shares in existence, roughly 60 shares are currently held short) or 0.0726% of the tradable shares (for every 100,000 tradable Lexaria Bioscience shares, roughly 73 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lexaria Bioscience.
Find out more about how you can short Lexaria Bioscience stock.
We're not expecting Lexaria Bioscience to pay a dividend over the next 12 months.
You may also wish to consider:
Lexaria Bioscience's shares were split on a 1:30 basis on 11 January 2021. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexaria Bioscience shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Lexaria Bioscience shares which in turn could have impacted Lexaria Bioscience's share price.
Over the last 12 months, Lexaria Bioscience's shares have ranged in value from as little as $4.11 up to $10.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexaria Bioscience's is 1.5079. This would suggest that Lexaria Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Lexaria Bioscience's beta into context you can compare it against those of similar companies.
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.